Tim Brümmendorf

Head

University Hospital RWTH Aachen

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Tim Brümmendorf serves as the Head at Uniklinik RWTH Aachen in Germany. His research areas include chronic myeloid leukemia, multiple myeloma, immune checkpoint blockade, and hematopoietic stem cell transplantation. He has contributed to significant studies highlighting the efficacy and safety of treatments like bosutinib and pomalidomide, as well as the implications of genetic variants in hematologic disorders.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (8)

Elisabetta Abruzzese

UNIVERSITY TOR VERGATA

ITALY

View details

Martin Zenke

GERMANY

View details

Tiago Maié

Rheinisch Westfälische Technische Hochschule Aachen RWTH Aachen Fakultät für Mathematik Informatik und Naturwissenschaft

GERMANY

View details

Leo Hansmann

GERMANY

View details

Peter Boor

University Hospital RWTH Aachen

GERMANY

View details

Steffen Koschmieder

RWTH Aachen University

GERMANY

View details

CARLO GAMBACORTI PASSERINI

Full Professor of Hematology

University of Milano-Bicocca

ITALY

View details

Valentin Garcia

Profesor Asociado

Universidad de Alcalá

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tim Brümmendorf

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma

Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial

Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies

Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry

Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study

KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile

Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms

DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation

Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

Collaborators (8)

Elisabetta Abruzzese

Martin Zenke

Tiago Maié

Leo Hansmann

Peter Boor

Steffen Koschmieder

CARLO GAMBACORTI PASSERINI

Valentin Garcia

Make your next move.